Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Glaukos Corporation
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
Glaukos Corp. said it expects rising competition in the US microinvasive glaucoma surgery (MIGS) space in 2020 from Ivantis along with surgical procedures.
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.
- Controlled Release
- Topical Delivery
- Drug Delivery
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Avedro, Inc.
- DOSE Medical Corporation
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.